Baseline characteristics of patients with NLPHL
| Characteristic . | Result . | Data available . |
|---|---|---|
| Median age at diagnosis (range), years | 41 (16-73) | 59 |
| Male (%) | 44 (75) | 59 |
| Histologic type (%) | 59 | |
| Typical (A/B) | 36 (61) | |
| Variant (non-A/B) | 19 (32) | |
| Histologic transformation at diagnosis | 4 (7) | |
| DLBCL | 3 (75) | |
| TCRBCL | 1 (25) | |
| Albumin <4.0 g/dL (%) | 7 (13) | 55 |
| GHSG score | 59 | |
| Low risk (0-1) | 14 (24%) | |
| Intermediate risk (2) | 28 (48%) | |
| High risk (3-4) | 17 (29%) | |
| Stage (%) | 59 | |
| I | 12 (20) | |
| II | 25 (42) | |
| III | 14 (24) | |
| IV | 8 (14) | |
| ECOG performance status (%) | 53 | |
| 0 | 33 (62) | |
| 1 | 20 (38) | |
| B symptoms (%) | 8 (14) | 59 |
| Extranodal sites of involvement (%) | 9 (15) | 59 |
| Spleen involved (%) | 8 (14) | 59 |
| Bone marrow involved (%) | 5 (8) | 59 |
| Characteristic . | Result . | Data available . |
|---|---|---|
| Median age at diagnosis (range), years | 41 (16-73) | 59 |
| Male (%) | 44 (75) | 59 |
| Histologic type (%) | 59 | |
| Typical (A/B) | 36 (61) | |
| Variant (non-A/B) | 19 (32) | |
| Histologic transformation at diagnosis | 4 (7) | |
| DLBCL | 3 (75) | |
| TCRBCL | 1 (25) | |
| Albumin <4.0 g/dL (%) | 7 (13) | 55 |
| GHSG score | 59 | |
| Low risk (0-1) | 14 (24%) | |
| Intermediate risk (2) | 28 (48%) | |
| High risk (3-4) | 17 (29%) | |
| Stage (%) | 59 | |
| I | 12 (20) | |
| II | 25 (42) | |
| III | 14 (24) | |
| IV | 8 (14) | |
| ECOG performance status (%) | 53 | |
| 0 | 33 (62) | |
| 1 | 20 (38) | |
| B symptoms (%) | 8 (14) | 59 |
| Extranodal sites of involvement (%) | 9 (15) | 59 |
| Spleen involved (%) | 8 (14) | 59 |
| Bone marrow involved (%) | 5 (8) | 59 |